Maxpro Capital Acquisition Corp.
JMACU
NASDAQ Global Market11.20
USD
-0.81
- -
CIK
0001874259
ISIN
US57778T2050
CUSIP
57778T205
Return %
Stock
S&P500
1Y
9.59
26.53
3Y
10.78
76.60
5Y
10.78
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Hong-Jung Chen
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- No. 89 Songren Road Taipei Taiwan, Province of China 11073
- IPO Date
- Oct 5, 2021
- CIK
- 0001874259
- Similar Companies
- Business
- Maxpro Capital Acquisition Corp. is a special purpose acquisition company (SPAC) primarily focused on effecting mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations. Founded in 2021 and headquartered in Taipei, Taiwan, the company operates as a blank check company without significant standalone operations or core products. Its primary industry classification is diversified financials, specifically asset management and custody banks. Maxpro Capital Acquisition Corp. targets business combinations in industries complementary to its management team's expertise. A key recent strategic development is its definitive agreement in 2022 for a business combination with Apollomics Inc., a late-stage clinical biopharmaceutical company specializing in oncology therapies. This transaction, valued at an implied pre-money equity of approximately $899 million, is expected to transition Apollomics into a publicly traded company on the Nasdaq Global Market, where it will trade under the ticker symbol APML. The combined entity aims to leverage up to $105 million in cash proceeds to finance growth opportunities and expand drug development pipelines focused on difficult-to-treat cancers. The company raised approximately $90 million in its initial public offering in 2021 and operates primarily within the financial and investment sector as a vehicle for acquiring operating businesses rather than manufacturing or selling its own products. Its recent operational focus has centered on finalizing the business combination with Apollomics, scheduled for completion in early 2023, which marks a significant strategic shift toward the biopharmaceutical industry. Maxpro Capital Acquisition Corp. maintains its headquarters at 5/F-4, No. 89 Songren Road, Xinyi District, Taipei City, Taiwan. It has no direct subsidiaries but functions as a vehicle for strategic acquisitions and capital deployment in targeted industries. The company is listed on the Nasdaq under the tickers JMAC, JMACU, and JMACW. Maxpro's latest major change is the completion of its SPAC merger agreement, which positions it as a bio-pharmaceutical consolidator post-transaction, thus expanding its business scope beyond its original financial sector focus into biotechnology and clinical-stage drug development. Its management emphasizes supporting the vision of transforming oncology treatment through innovative product candidates.